Rajeeva Singh
Impact in
-
- Monoclonal and Polyclonal Antibodies Research
- Oncology top 2%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
-
- Advanced Biosensing Techniques and Applications 4
- Oncology 19
- HER2/EGFR in Cancer Research 19
- Co-authors
- George M. Whitesides (6 shared papers)Erin K. Maloney (12 shared papers)Wayne C. Widdison (8 shared papers)Ravi Chari (16 shared papers)Hans K. Erickson (8 shared papers)Sharon Wilhelm (6 shared papers)John M. Lambert (5 shared papers)Kathleen R. Whiteman (5 shared papers)
- Journals
- Molecular Cancer Therapeutics (7 papers)Bioconjugate Chemistry (4 papers)Cancer Research (4 papers)Analytical Biochemistry (4 papers)Molecular Pharmaceutics (3 papers)
- Partner nations
- United StatesIndiaUnited Kingdom
In The Last Decade
Rajeeva Singh
51 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 105
- Radiology, Nuclear Medicine and Imaging 772
- Oncology 892
- Toxicology 49
- Endocrinology, Diabetes and Metabolism 225
- Molecular Biology 855
Countries citing papers authored by Rajeeva Singh
This map shows the geographic impact of Rajeeva Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajeeva Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajeeva Singh more than expected).
Fields of papers citing papers by Rajeeva Singh
This network shows the impact of papers produced by Rajeeva Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajeeva Singh. The network helps show where Rajeeva Singh may publish in the future.
Co-authors
The 25 scholars most cited alongside Rajeeva Singh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. | 2003 | 260 |
| 2 | 2010 | 199 | |
| 3 | 2009 | 175 | |
| 4 | 2015 | 164 | |
| 5 | 2011 | 154 | |
| 6 | 2011 | 154 | |
| 7 | 2006 | 99 | |
| 8 | 1990 | 95 | |
| 9 | 2011 | 66 | |
| 10 | 1991 | 66 | |
| 11 | 2016 | 65 | |
| 12 | 1993 | 54 | |
| 13 | 2002 | 53 | |
| 14 | 1996 | 51 | |
| 15 | 1987 | 44 | |
| 16 | 1995 | 43 | |
| 17 | 2011 | 38 | |
| 18 | 1995 | 37 | |
| 19 | 2019 | 35 | |
| 20 | 2008 | 30 |
About Rajeeva Singh
Rajeeva Singh is a scholar working on Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging, Organic Chemistry and Endocrinology, Diabetes and Metabolism, having authored 56 papers that have together received 2.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (18 papers), Growth Hormone and Insulin-like Growth Factors (5 papers), Sulfur-Based Synthesis Techniques (5 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Click Chemistry and Applications (4 papers), Advanced Biosensing Techniques and Applications (4 papers) and Chemical Synthesis and Reactions (4 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (772 citations), Oncology (892 citations), Toxicology (49 citations), Endocrinology, Diabetes and Metabolism (225 citations) and Molecular Biology (855 citations). Rajeeva Singh has collaborated with scholars based in United States, India and United Kingdom. Frequent co-authors include George M. Whitesides, Erin K. Maloney, Wayne C. Widdison, Ravi Chari, Hans K. Erickson, Sharon Wilhelm, John M. Lambert, Kathleen R. Whiteman, Charlene A. Audette and Walter A. Blättler. Their work appears in journals such as Molecular Cancer Therapeutics, Bioconjugate Chemistry, Cancer Research, Analytical Biochemistry and Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.